ExpressPoints: The New Biomarkers Pathologists Need to Know for Precision Therapy in Lung Cancer

Downloadable CCO resource summarizing best practices for detection of RET gene alterations in lung and thyroid tumors

Downloadable CCO resource summarizing efficacy data for recently FDA-approved next-generation RET inhibitors in lung and thyroid cancers

Short downloadable CCO resource summarizing approved indications, dosing, and key safety data for the selective RET inhibitors pralsetinib and selpercatinib

Download slides reviewing the latest clinical data informing optimal treatment of patients with RET-altered NSCLC and thyroid cancer, from Clinical Care Options

Taofeek K. Owonikoko, MD, PhD Released: January 21, 2021